Laboratory testing for infection with the human immunodeficiency virus: Established and novel approaches

American Journal of Medicine

Volumn 109, Issue 7, 2000, Pages 568-576

  Mylonakis, Eleftherios ^a   Paliou, Maria ^b   Lally, Michelle ^b   Flanigan, Timothy P ^b   Rich, Josiah D ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIGEN DETECTION; COST BENEFIT ANALYSIS; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; MOUTH MUCOSA; PRIORITY JOURNAL; RELIABILITY; REVIEW; SCREENING TEST; URINALYSIS; VAGINA SMEAR; VIRUS CULTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; BODY FLUIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; HIV; HIV INFECTIONS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 0033760553     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00583-0     Document Type: Review

References (80)

1. False-positive human immunodeficiency virus testing in patients with lupus erythematosus
2. Diagnostic tests for HIV
3. False-positive human immunodeficiency virus type 1 western blot tests in noninfected blood donors
4. Factitious HIV infection: The importance of documenting infection
5. Review of testing for human immunodeficiency virus
6. The baron has AIDS: A case of factitious human immunodeficiency virus infection and review
7. Fraudulent AIDS: A variant of Munchausen's syndrome
8. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV status
9. Laboratory diagnosis of human immunodeficiency virus infection
10. False-positive HIV antibody tests in RPR-reactive patients
11. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: Lessons from a phase II trial
12. Utility of quantitative enzyme immunoassay reactivity for predicting human immunodeficiency virus seropositivity in low- and high-prevalence populations
13. AIDS serology testing in low- and high-risk groups
14. Human immunodeficiency virus test evaluation, performance, and use. Proposals to make good tests better
15. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections
16. Update: Serologic testing for HIV-1 antibody - United States, 1988 and 1989
17. New anti-human immunodeficiency virus immunoblot assays resolve nonspecific western blot results
18. Reliable confirmation and quantitation of human immunodeficiency virus type 1 antibody using a recombinant-antigen immunoblot assay
19. HLA antigen contamination of commercial Western blot strips for detecting human immunodeficiency virus
20. Indeterminate human immunodeficiency virus type 1 western blots: Seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation
21. Indeterminate results of HIV testing: Explanation and clinical management
22. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications
23. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case-control study
24. What do Western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors?
25. Identification of regions of HIV-1 p24 reactive with sera which give 'indeterminate' results in electrophoretic immunoblots with the help of long synthetic peptides
26. Long-term follow-up of blood donors with indeterminate human immunodeficiency virus type 1 results on Western blot
27. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel
28. Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design
29. Management of blood donors whose donations are repeatedly falsely positive by the HIV antibody screening test
30. Detection of human immunodeficiency virus type 1 p24 antigen and plasma RNA: Relevance to indeterminate serologic tests
31. Diagnosis of perinatal human immunodeficiency virus infection by polymerase chain reaction and p24 antigen detection after immune complex dissociation in an urban community hospital
32. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection
33. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: A case series
34. False-positive HIV diagnosis by HIV-1 plasma viral load testing
35. A closed tube format for amplification and detection of DNA based on energy transfer
36. Automated closed-vessel system for in vitro diagnostics based on polymerase chain reaction
37. Interpretation of indeterminate HIV serology results in an incarcerated population
38. Immune control of HIV-1 after early treatment of acute infection
39. Measurement of the false positive rate in a screening program for human immunodeficiency virus infections
40. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study
41. An unusual case of false-positive serology for the human immunodeficiency virus: Report from the heterosexual HIV transmission study
42. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients
43. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections
44. Prevalence of HIV-1 subtype O infection in Cameroon: Preliminary results
45. Surveillance for human immunodeficiency virus type 1 group O infections in the United States
46. Implications of HIV variability for transmission: Scientific and policy issues. Expert Group of the Joint United Nations Programme on HIV/AIDS
47. Update. HIV counseling and testing using rapid tests - United States, 1995
48. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine(GECSA)
49. Time to hit HIV, early and hard
50. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: An overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group
51. Mother-to-child transmission of the human immunodeficiency virus
52. Rapid testing for HIV antibody: A technology whose time has come
53. Reducing the cost of HIV antibody testing
54. Comparative evaluation of six rapid serological tests for HIV-1 antibody
55. Field evaluation of alternative HIV testing strategy with a rapid immunobinding assay and an agglutination assay
56. Field testing and comparative evaluation of rapid, visually read screening assays for antibody to human immunodeficiency virus
57. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras
58. On-site HIV testing in resource-poor settings: Is one rapid test enough?
59. Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus
60. Evaluation of two rapid screening assays for the detection of human immunodeficiency virus-1 infection in emergency department patients
61. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. CDC-Bronx-Lebanon HIV Serosurvey Team
62. Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting
63. Direct HIV testing in blood donations: Variation of the yield with detection threshold and pool size
64. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors
65. Home screening kit for HIV approved
66. Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation
67. Home HIV testing and conflicts with state HIV testing regulations
68. Testing for HIV infection at home
69. Home sample collection tests for HIV infection
70. A comparative study of saliva and OraSure oral fluid
71. Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. OraSure HIV Clinical Trials Group
72. Detection of antibody to HIV-1 in urine
73. Urine antibody tests: New insights into the dynamics of HIV-1 infection
74. STD Treatment Guidelines
75. Detection of antibodies to human immunodeficiency virus in vaginal secretions by immunoglobulin G antibody capture enzyme-linked immunosorbent assay: Application to detection of seminal antibodies after sexual intercourse
76. Testing of saliva and serum for HIV in high-risk populations. Ad Hoc Group for the Comparative Saliva and Serum Study
77. Successful use of pooled sera to determine HIV-1 seroprevalence in Zaire with development of cost-efficiency models
78. Cost reduction of unlinked testing for anti-HIV by investigation of pooled sera
79. Relevance of antibody content and test format in HIV testing of pooled sera
80. Diagnosis of acute HIV infection: It's time to get moving